The IL-6 levels in patients with CRS ≥ 2 during CD19 CAR-T therapy were significantly higher than those in patients with CRS ≥ 2 during CD22 CAR-T therapy (P = 0.03), while no significant differences were observed for other cytokines (Fig. S3). This evidence concerns the gene IL6 and congenital rubella syndrome.